Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the impact of pelvic node irradiation.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2022
Historique:
received: 14 03 2022
revised: 12 07 2022
accepted: 01 08 2022
pubmed: 8 8 2022
medline: 21 10 2022
entrez: 7 8 2022
Statut: ppublish

Résumé

Explainable models of long-term risk of biochemical failure (BF) after post-prostatectomy salvage radiotherapy (SRT) are lacking. A previously introduced radiobiology-based formula was adapted to incorporate the impact of pelvic nodes irradiation (PNI). The risk of post-SRT BF may be expressed by a Poisson-based equation including pre-SRT PSA, the radiosensitivity α, the clonogen density C, the prescribed dose (in terms of EQD2, α/β = 1.5 Gy) and a factor (1-BxλxPSA) accounting for clonogens outside the irradiated volume, being λ the recovery due to PNI. Data of 795 pT2-pT3, pN0/pN1/pNx (n = 627/94/74) patients with follow-up ≥ 5 years and pre-RT PSA ≤ 2 ng/mL were randomly split into training (n = 528) and validation (n = 267) cohorts; the training cohort data were fitted by the least square method. Separate fits were performed for different risk groups. Model performances were assessed by calibration plots and tested in the validation group. The median follow-up was 8.5y, median pre-SRT PSA and EQD2 were 0.43 ng/mL and 71.3 Gy respectively; 331/795 pts received PNI. The most clinically significant prognostic grouping was pT3b and/or ISUP4-5 versus pT2/3a and ISUP1-3. Best-fit parameters were α An explainable one-size-fits-all equation satisfactorily predicts long-term risk of post-SRT BF. The model was independently validated. A calculator tool was made available.

Sections du résumé

BACKGROUND AND PURPOSE
Explainable models of long-term risk of biochemical failure (BF) after post-prostatectomy salvage radiotherapy (SRT) are lacking. A previously introduced radiobiology-based formula was adapted to incorporate the impact of pelvic nodes irradiation (PNI).
MATERIALS AND METHODS
The risk of post-SRT BF may be expressed by a Poisson-based equation including pre-SRT PSA, the radiosensitivity α, the clonogen density C, the prescribed dose (in terms of EQD2, α/β = 1.5 Gy) and a factor (1-BxλxPSA) accounting for clonogens outside the irradiated volume, being λ the recovery due to PNI. Data of 795 pT2-pT3, pN0/pN1/pNx (n = 627/94/74) patients with follow-up ≥ 5 years and pre-RT PSA ≤ 2 ng/mL were randomly split into training (n = 528) and validation (n = 267) cohorts; the training cohort data were fitted by the least square method. Separate fits were performed for different risk groups. Model performances were assessed by calibration plots and tested in the validation group.
RESULTS
The median follow-up was 8.5y, median pre-SRT PSA and EQD2 were 0.43 ng/mL and 71.3 Gy respectively; 331/795 pts received PNI. The most clinically significant prognostic grouping was pT3b and/or ISUP4-5 versus pT2/3a and ISUP1-3. Best-fit parameters were α
CONCLUSION
An explainable one-size-fits-all equation satisfactorily predicts long-term risk of post-SRT BF. The model was independently validated. A calculator tool was made available.

Identifiants

pubmed: 35934169
pii: S0167-8140(22)04222-0
doi: 10.1016/j.radonc.2022.08.001
pii:
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

26-32

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Cesare Cozzarini (C)

Radiotherapy, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Michela Olivieri (M)

Medical Physics, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Alessandro Magli (A)

Radiotherapy, Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, Italy.

Domenico Cante (D)

Radiotherapy, ASL TO4, Ospedale di Ivrea, Ivrea, Italy.

Barbara Noris Chiorda (B)

Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Fernando Munoz (F)

Radiotherapy, Ospedale Regionale Parini-AUSL Valle d'Aosta, Aosta, Italy.

Adriana Faiella (A)

Radiotherapy, IRCCS Istituto Nazionale dei Tumori "Regina Elena", Roma, Italy.

Elisa Olivetta (E)

Radiotherapy, A.O.SS. Antonio e Biagio, Alessandria, Italy.

Chiara Deantoni (C)

Radiotherapy, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Andrei Fodor (A)

Radiotherapy, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Marco Andrea Signor (MA)

Radiotherapy, Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, Italy.

Edoardo Petrucci (E)

Radiotherapy, ASL TO4, Ospedale di Ivrea, Ivrea, Italy.

Barbara Avuzzi (B)

Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Letizia Ferella (L)

Radiotherapy, Ospedale Regionale Parini-AUSL Valle d'Aosta, Aosta, Italy.

Alice Pastorino (A)

Radiotherapy, A.O.SS. Antonio e Biagio, Alessandria, Italy.

Elisabetta Garibaldi (E)

Radiotherapy, Candiolo Cancer Institute - FPO, IRCCS, Torino, Italy.

Marco Gatti (M)

Radiotherapy, Candiolo Cancer Institute - FPO, IRCCS, Torino, Italy.

Luciana Rago (L)

Centro di Riferimento Oncologico della Basilicata (IRCCS - CROB), Rionero in Vulture, PZ, Italy.

Teodora Statuto (T)

Centro di Riferimento Oncologico della Basilicata (IRCCS - CROB), Rionero in Vulture, PZ, Italy.

Tiziana Rancati (T)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Alberto Briganti (A)

Division of Experimental Oncology/Unit of Urology, URI, Urological Research Unit, San Raffaele Scientific Institute, Milano, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Francesco Montorsi (F)

Division of Experimental Oncology/Unit of Urology, URI, Urological Research Unit, San Raffaele Scientific Institute, Milano, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Riccardo Valdagni (R)

Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Giuseppe Sanguineti (G)

Radiotherapy, IRCCS Istituto Nazionale dei Tumori "Regina Elena", Roma, Italy.

Nadia Gisella Di Muzio (NG)

Radiotherapy, IRCCS San Raffaele Scientific Institute, Milano, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Claudio Fiorino (C)

Medical Physics, IRCCS San Raffaele Scientific Institute, Milano, Italy. Electronic address: fiorino.claudio@hsr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH